Blue M Tech Swings to Q3 Profit; Sets ₩50 Billion Sales Record

Blue M-Tech recorded remarkable performance in the third quarter of 2025, with robust revenue growth and a successful turnaround to an operating profit surplus. Consolidated revenue reached approximately KRW 52.1 billion, showing a high growth rate of 14.2% compared to the previous quarter and 10.6% compared to the same period last year. Driven by this growth momentum, cumulative revenue until the third quarter reached approximately KRW 132.0 billion, and with the fourth-quarter performance added, it is expected to comfortably surpass last year's total revenue (approximately KRW 133.0 billion). The company explained that the successful launch of Mounjaro, a major obesity treatment, and the expansion of Wegovy's sales served as key growth drivers. Furthermore, customer-centric service enhancement strategies such as same-day delivery service expanded across Seoul, membership renewal, and webinars also played a crucial role in driving performance. In terms of profitability, the results are even more encouraging. Operating profit recorded approximately KRW 350 million, an increase of KRW 1.1 billion compared to the previous quarter, successfully turning into a surplus. Although net profit for the period showed a loss of approximately KRW 490 million, it significantly reduced the deficit compared to the previous quarter, indicating an improvement. Blue M-Tech expects that in the fourth quarter as well, the continued growth of seasonal products such as influenza vaccines and the obesity treatment market will have a positive impact. The company's strategy is to make 2025 a turning point for solid profitability improvement through cost efficiency and focusing on core business capabilities.